How to buy Laboratory Corporation of America (LH) shares in Australia

Learn how to easily invest in Laboratory Corporation of America shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Laboratory Corporation of America Holdings (LH) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$286.97 after a previous close of US$285.45. During the day the price has varied from a low of USD286.44 to a high of USD293.535. The latest price was USD291.21 (25 minute delay). Laboratory Corporation of America is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Laboratory Corporation of America

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Laboratory Corporation of America. Find the share by name or ticker symbol: LH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Laboratory Corporation of America reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$285.45, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Laboratory Corporation of America, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Laboratory Corporation of America. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Laboratory Corporation of America stock price (NYSE:LH)

Use our graph to track the performance of LH stocks over time.

Laboratory Corporation of America shares at a glance

Information last updated 2021-12-02.
OpenUS$286.97
HighUS$293.535
LowUS$286.44
CloseUS$291.21
Previous closeUS$285.45
Change US$5.76
Change % 2.0179%
Volume 224,380
Information last updated 2021-11-27.
52-week rangeUS$195.88 - US$309.6
50-day moving average US$283.5048
200-day moving average US$273.7181
Target priceUS$336.14
PE ratio 10.2636
Dividend yield N/A (0%)
Earnings per share (TTM) US$28.187

Where to buy Laboratory Corporation of America stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CommSec Share Trading Account
US$19.95
0.60%
ASX shares, Global shares, Options trading, ETFs
Trade with Australia's largest online stockbroking firm.
Enjoy fast, simple and affordable trades, with market leading research and broker recommendations all in one platform
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Laboratory Corporation of America stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Laboratory Corporation of America share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Laboratory Corporation of America shares?

Before you consider Laboratory Corporation of America, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Laboratory Corporation of America price performance over time

Historical closes compared with the last close of $291.21

1 week (2021-11-24) 2.64%
1 month (2021-11-02) 1.74%
3 months (2021-09-02) -5.56%
6 months (2021-06-02) 10.51%
1 year (2020-12-02) 46.45%
2 years (2019-12-02) 68.72%
3 years (2018-11-30) 99.95%
5 years (2016-12-02) 133.94%

Is Laboratory Corporation of America under- or over-valued?

Valuing Laboratory Corporation of America stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Laboratory Corporation of America's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Laboratory Corporation of America's P/E ratio

Laboratory Corporation of America's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Laboratory Corporation of America shares trade at around 10x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Laboratory Corporation of America's PEG ratio

Laboratory Corporation of America's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0682. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Laboratory Corporation of America's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Laboratory Corporation of America's EBITDA

Laboratory Corporation of America's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$4.6 billion (£3.5 billion).

The EBITDA is a measure of a Laboratory Corporation of America's overall financial performance and is widely used to measure a its profitability.

Laboratory Corporation of America financials

Revenue TTM US$16.6 billion
Operating margin TTM 24.76%
Gross profit TTM US$5 billion
Return on assets TTM 12.94%
Return on equity TTM 29.4%
Profit margin 16.69%
Book value 109.859
Market capitalisation US$27.7 billion

TTM: trailing 12 months

Laboratory Corporation of America's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Laboratory Corporation of America.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Laboratory Corporation of America's total ESG risk score

Total ESG risk: 19.26

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Laboratory Corporation of America's overall score of 19.26 (as at 12/31/2018) is excellent – landing it in it in the 15th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Laboratory Corporation of America is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Laboratory Corporation of America's environmental score

Environmental score: 4.17/100

Laboratory Corporation of America's environmental score of 4.17 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Laboratory Corporation of America is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Laboratory Corporation of America's social score

Social score: 11.07/100

Laboratory Corporation of America's social score of 11.07 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Laboratory Corporation of America is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Laboratory Corporation of America's governance score

Governance score: 13.02/100

Laboratory Corporation of America's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Laboratory Corporation of America is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Laboratory Corporation of America's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Laboratory Corporation of America scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Laboratory Corporation of America has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Laboratory Corporation of America Holdings was last rated for ESG on: 2019-01-01.

Total ESG score 19.26
Total ESG percentile 14.56
Environmental score 4.17
Environmental score percentile 7
Social score 11.07
Social score percentile 7
Governance score 13.02
Governance score percentile 7
Level of controversy 2

Laboratory Corporation of America share dividends

We're not expecting Laboratory Corporation of America to pay a dividend over the next 12 months.

Have Laboratory Corporation of America's shares ever split?

Laboratory Corporation of America's shares were split on a 2:1 basis on 12 May 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Laboratory Corporation of America shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Laboratory Corporation of America shares which in turn could have impacted Laboratory Corporation of America's share price.

Laboratory Corporation of America share price volatility

Over the last 12 months, Laboratory Corporation of America's shares have ranged in value from as little as US$195.88 up to US$309.6. A popular way to gauge a stock's volatility is its "beta".

LH.US volatility(beta: 1.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Laboratory Corporation of America's is 1.0068. This would suggest that Laboratory Corporation of America's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Laboratory Corporation of America overview

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company has a collaboration agreement with community clinical oncology research network, LLC to understand the impact of disparities in precision medicine for people with cancer; and strategic collaboration with GeneCentric Therapeutics, Inc. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site